EpCAM- AN OLD CANCER ANTIGEN, TURNED ONCOGENIC RECEPTOR AND ITS TAGETING IMMUNOTHERAPY
Author(s) -
George Zhu
Publication year - 2018
Publication title -
universal journal of pharmaceutical research
Language(s) - English
Resource type - Journals
ISSN - 2456-8058
DOI - 10.22270/ujpr.v3i2.140
Subject(s) - pi3k/akt/mtor pathway , cancer research , cancer , epithelial cell adhesion molecule , mapk/erk pathway , protein kinase b , immunotherapy , medicine , biology , signal transduction , microbiology and biotechnology
EpCAM is a cell adhesion molecule. Its structure, its expression and the oncogenic potential, and its signaling network and target therapy were in concise reviewed. In recent advances,in addition to PI3K/akt and Raf/MAPK pathway involving in cell survival,anti-apoptosis and proliferation,and malignant initiation and progression(see figure by Zhu,1986-91), three distinct pathway are illustrated: EpCAM/E-cadherin-catenin-actin cytoskeleton, EpCAM/ wint-catenin signaling and its major EpCAM/ nuclear signaling presented by Maetzel D in 2009 and Munz M in 2004. Moreover, more accumulated data are needed in detail mechanism. The data may provide its cancer biology and clinical targeting therapy benefits. Google Scholar
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom